ccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002, 99(5):1517-26
25. O\'Reilly RJ, Small TN, Papadopoulos E, et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997, 157:195-216
26. Lucas KG, Salzman D, Garcia A, et al. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer. 2004, 100(9):1892-901
27. Leonard JP, Coleman M, Vose J, et al. Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma (MCL). Proc Am Soc Clin Oncol 2003, Abstract No: 2276
28. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003,348(26):2609-17
29. Connor O. A. O\'. Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL). Proc Am Soc Clin Oncol 2004, Abstract No: 6582
